Harmony Biosciences (HRMY)

• Market cap: $2.1B
• 1 day: 8.95%
• 5 days: 6.99%
• 1 month: 13.89%
• 3 months: 3.97%
• 6 months: 8.47%
• Year to date: 5.91%
• 1 year: 14.74%
• 5 years: -0.32%
• 10 years: -0.32%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Employees: 246

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

119% more call options, than puts

Call options by funds: $4.39M | Put options by funds: $2M

63% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 24

29% more capital invested

Capital invested by funds: $1.54B [Q2] → $2B (+$454M) [Q3]

20% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]

6% more funds holding

Funds holding: 218 [Q2] → 230 (+12) [Q3]

2.17% less ownership

Funds ownership: 90.05% [Q2] → 87.88% (-2.17%) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 86

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $52 41% upside
• Avg. target: $61 65% upside
• High target: $75 103% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ami Fadia 34% 1-year accuracy 56 / 166 met price target	41% upside $52	Buy Reiterated	13 Jan 2025
HC Wainwright & Co. Patrick Trucchio 38% 1-year accuracy 61 / 160 met price target	103% upside $75	Buy Initiated	17 Dec 2024
Cantor Fitzgerald Charles Duncan 43% 1-year accuracy 35 / 82 met price target	57% upside $58	Overweight Maintained	30 Oct 2024
Oppenheimer Francois Brisebois 46% 1-year accuracy 16 / 35 met price target	60% upside $59	Outperform Reiterated	30 Oct 2024